Wellnex Life's acquisition update

Wellnex Life (ASX:WNX), a consumer healthcare company, announced a delay in the payment of the deferred consideration for its acquisition of Pain Away. Originally scheduled for October 2024, the payment is now set for January 2025. This adjustment aligns with Wellnex Life's strategic plan to dual list on the London Stock Exchange Main Board.

Outlook on Wellnex Life's strategic plans

Wellnex Life is adjusting its financial strategy by delaying the deferred payment for the Pain Away acquisition to January 2025. This change supports their upcoming dual listing on the LSE, intended to enhance their financial health and international reach. The company aims to leverage this listing to access UK-based investors, retire debts, and accelerate global expansion. Pain Away continues to perform strongly, reinforcing Wellnex Life's market position. Preparations for the LSE listing are underway, with a prospectus expected to be approved soon, reflecting Wellnex Life's ambition to grow and solidify its international presence.

Executive insights on strategic alignment

The deferred payment aligns with our dual listing on the LSE. This move will help us retire debts and facilitate further international expansion.